IDEXX Laboratories Raises FY2026 GAAP EPS Guidance from $14.29-$14.80 to $14.45-$14.90 vs $14.53 Est; Raises FY2026 Sales Guidance from $4.632B-$4.720B to $4.675B-$4.760B vs $4.678B Est

IDEXX Laboratories (NASDAQ:IDXX) raises FY2026 GAAP EPS guidance from $14.29-$14.80 to $14.45-$14.90 vs $14.53 analyst estimate. Raises FY2026 sales outlook from $4.632 billion-$4.720 billion to $4.675 billion-$4.760 billion vs $4.678 billion estimate.